Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes. (Q50077356)

24 February 2018

title

Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes. (English)

1 reference

24 February 2018

1 reference

Ignacio Conget

1

1 reference

24 February 2018

M Sue Kirkman

2

1 reference

24 February 2018

Dachuang Cao

3

1 reference

24 February 2018

Mayme Wong

4

1 reference

24 February 2018

Jesus Reviriego

5

1 reference

24 February 2018

David M Kendall

6

1 reference

24 February 2018

language of work or name

English

0 references

publication date

24 October 2017

1 reference

24 February 2018

Current Medical Research and Opinion

published in

1 reference

24 February 2018

volume

34

1 reference

24 February 2018

page(s)

329-336

1 reference

24 February 2018

issue

2

1 reference

24 February 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Diabetes performance measures: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1396968

10.1080/03007995.2017.1396968

21 January 2018

Identifiers

DOI

1 reference

24 February 2018

PubMed ID

29065720

1 reference

24 February 2018